Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Nvsef source : Www.globenewswire.com save search
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Published: 2024-04-17 (Crawled : 06:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.87%
H: 0.16%
C: -0.59%
kesimpta sclerosis novartis show benefits
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -1.94%
H: 0.43%
C: -0.34%
OCUL | News | $5.86 -22.69% -29.35% 6.1M
|
Health Technology
|
| O: -1.03%
H: 3.66%
C: 1.7%
ocular key leaders
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Published: 2024-04-15 (Crawled : 18:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
fabhalta nephropathy for novartis show
Novartis tender offer for MorphoSys AG commences
Published: 2024-04-11 (Crawled : 09:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.32%
H: 0.48%
C: -0.17%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.32%
H: 0.04%
C: -0.56%
MOR | $18.02 -0.11% -0.11% 590K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: -0.39%
for novartis
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
Published: 2024-04-06 (Crawled : 20:20) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
| Email alert
Add to watchlist
leqvio novartis therapy show
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
NAMS | $19.415 -3.17% -3.27% 220K
|
n/a
|
| O: 6.23%
H: 2.77%
C: -10.21%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.47%
H: 0.23%
C: -0.99%
pharma business
CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
Published: 2024-03-28 (Crawled : 19:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
| Email alert
Add to watchlist
AVEO | $15.0 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
AUTL | $4.8 -0.83% -0.83% 1.2M
|
Health Technology
| Email alert
Add to watchlist
medical
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
Published: 2024-03-27 (Crawled : 20:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
ERAS | $1.795 -2.45% -2.51% 650K
|
|
| O: 17.48%
H: 6.94%
C: -14.88%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.28%
H: 1.71%
C: -0.3%
business year financial results
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.08%
H: 0.15%
C: -0.44%
AUTL | $4.8 -0.83% -0.83% 1.2M
|
Health Technology
|
| O: 2.53%
H: 1.85%
C: -2.31%
medical
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.17%
H: 0.28%
C: -0.01%
fabhalta first chmp positive novartis
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
Published: 2024-03-20 (Crawled : 10:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.37%
H: 0.0%
C: -1.58%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.62%
H: 0.45%
C: 0.34%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: -5.51%
H: 1.33%
C: 1.2%
management commercial
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
Published: 2024-03-04 (Crawled : 07:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.6%
H: 0.68%
C: 0.51%
children novartis
Genmab Publishes 2023 Annual Report
Published: 2024-02-14 (Crawled : 16:00) - globenewswire.com
GNMSF | $281.02 3.83% 210
|
Health Technology
|
| O: 2.65%
H: 4.56%
C: 1.23%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.02%
H: 0.24%
C: 0.01%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.91%
H: 0.0%
C: 0.0%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: 1.32%
H: 5.34%
C: 3.02%
report
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
Published: 2024-02-05 (Crawled : 22:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: -1.56%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.15%
H: 0.6%
C: 0.42%
MOR | $18.02 -0.11% -0.11% 590K
|
Health Technology
|
| O: 1.39%
H: 0.34%
C: -7.08%
pipeline acquire novartis agreement
Mondelēz International Appoints Brian McNamara to Board of Directors
Published: 2024-02-02 (Crawled : 14:00) - globenewswire.com
HLNCF | $3.94 -1.48% 1
|
n/a
|
| O: -2.64%
H: 1.6%
C: 1.48%
HLN | $8.13 0.25% -0.98% 4.8M
|
n/a
|
| O: -0.48%
H: 0.0%
C: -0.6%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.5%
H: 0.26%
C: -1.03%
MDLZ | $67.18 1.01% 1.0% 8.7M
|
Consumer Non-Durables
|
| O: 0.47%
H: 0.38%
C: -0.04%
international
Opthea Strengthens Team with Key Clinical and Regulatory Hires
Published: 2024-02-01 (Crawled : 11:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 1.55%
H: 0.79%
C: 0.25%
ALC | $78.47 -0.67% -0.01% 760K
|
Health Technology
|
| O: 0.24%
H: 1.54%
C: 1.46%
OPT | $3.41 0.29% 0.29% 2.7K
|
Health Technology
|
| O: -0.74%
H: 6.84%
C: 2.6%
key
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
Published: 2024-01-31 (Crawled : 06:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -2.04%
H: 0.19%
C: -1.97%
sales year momentum positive innovation novartis growth
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
Published: 2024-01-11 (Crawled : 13:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.22%
H: 0.43%
C: 0.37%
LNTH | News | $62.34 1.4% 1.38% 1.3M
|
Health Technology
|
| O: 0.32%
H: 0.03%
C: -4.42%
lutathera
Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia
Published: 2024-01-08 (Crawled : 07:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.89%
H: 0.12%
C: -0.17%
scemblix leukemia trial response molecular
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
Published: 2024-01-05 (Crawled : 14:30) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.24%
H: 1.43%
C: 1.43%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.32%
H: 0.93%
C: 0.38%
novartis advanced therapy
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.